Your browser doesn't support javascript.
loading
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.
Barrientos-Pérez, Margarita; Hsia, Daniel S; Sloan, Lance; Nell, Haylene; Mungur, Ounisha; Hovsepian, Lionel; Schmider, Wolfgang; Spranger, Robert; Yang, Na; Niemoeller, Elisabeth.
Afiliação
  • Barrientos-Pérez M; Department of Paediatric Endocrinology, Angeles Hospital of Puebla, Puebla City, Mexico.
  • Hsia DS; Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
  • Sloan L; Texas Institute for Kidney and Endocrine Disorders, Lufkin, Texas, USA.
  • Nell H; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
  • Mungur O; Tiervlei Trial Centre, Karl Bremer Hospital, Cape Town, South Africa.
  • Hovsepian L; CAP Research, Quatre Bornes, Mauritius.
  • Schmider W; Sanofi, Paris, France.
  • Spranger R; Sanofi, Frankfurt, Germany.
  • Yang N; Sanofi, Frankfurt, Germany.
  • Niemoeller E; Sanofi, Beijing, China.
Pediatr Diabetes ; 23(6): 641-648, 2022 09.
Article em En | MEDLINE | ID: mdl-35411611
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Diabetes Mellitus Tipo 2 / Hipoglicemiantes Idioma: En Ano de publicação: 2022 Tipo de documento: Article